Brief: Sienna Biopharmaceuticals Says Data Showed SNA-001 Met Primary Endpoint Of Non-Inferiority In Hair Reduction

Sienna Biopharmaceuticals

08/02/2019 14:11

Feb 8 (Reuters) - Sienna Biopharmaceuticals Inc  SNNA.O :
    * SIENNA BIOPHARMACEUTICALS’ NOVEL SILVER PHOTOPARTICLE
TECHNOLOGY
SNA-001 SUCCESSFULLY REMOVES  LIGHT HAIR WHEN USED WITH COMMON
LASER SYSTEM
    * SIENNA BIOPHARMACEUTICALS INC - SIENNA TO SEEK STRATEGIC
PARTNER
FOR SNA-001
    * SIENNA BIOPHARMACEUTICALS - WILL CONTINUE TO FOCUS ON
PHASE 3
DEVELOPMENT OF SNA-120 FOR PSORIASIS AND PRURITUS AND ITS
TOPICAL BY DESIGN PLATFORM
    * SIENNA BIOPHARMACEUTICALS INC - DATA SHOWED SNA-001 MET
PRIMARY
ENDPOINT OF NON-INFERIORITY IN HAIR REDUCTION
    * SIENNA BIOPHARMA - SNA-001 WAS STATISTICALLY SUPERIOR
COMPARED
TO VEHICLE+LASER, SHOWING UP TO A 31 PERCENT REDUCTION OF LIGHT
HAIR FROM BASELINE

Source text for Eikon:  ID:nGNX2smqZD 
Further company coverage:  SNNA.O 

 (Reuters.Briefs@thomsonreuters.com)